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Editorial on the Research Topic
Advances in Liver Inflammation and Fibrosis Due to Infectious Diseases
Liver inflammation is a common trigger of hepatic disease, and it is considered the main driver
of tissue damage (1). Although the liver is able to regenerate, chronic liver inflammation leads to
tissue damage with concomitant fibrosis, frequently leading to cirrhosis, and carcinogenesis (2).
The etiology of chronic liver inflammation may be infectious or not. Several microorganisms
including bacteria, parasites, fungi, and virus could be involved. Although, other metabolic and
immune disorders may also participate. Several proinflammatory cytokines including IL-1α, IL-1β,
TNF-α, and IL-6 has been involved in liver disease (3). They are produced by resident macrophages
(Kupffer cells) and also by recruited macrophages and neutrophils (4). The common mediators
of fibrosis are IL-10 family cytokines, VEGF, EGF, and TGF-β that constitute the main profibrotic
cytokines (5). TGF-β stimulate hepatic stellate cell trans-differentiation from a quiescent, vitamin
A storing cell to a proliferative myofibroblast that is the central driver of fibrosis (6).
In this Research Topic, a series of articles provide new insights about the current view of liver
pathology, inflammation and fibrosis, with original articles about the role of myeloid suppressor
cells in fulminant hepatitis, inflammasome activation in brucellosis, new insights in preventing
NALDF progression, and the role of NLRP6 in granuloma formation and liver disease associated
with schistosomiasis.
This Research Topic also features three review articles regarding the role of glucocorticoids in
therapy of liver failure, the interaction of liver and immune cells in brucellosis, the role of T cells
in hepatic schistosomiasis, as well as the role of beneficial bacterial in liver disease progression.
Also included is a perspective article with proposed mechanisms of interaction between human
immunodeficiency virus (HIV) and Kupffer cells.
The original research articles included in this Research Topic were performed involving both in
vitro, and in vivo experiments in the murine model. Such model has acquired particular relevance
during the study of non-invasive biomarkers able to assess fibrosis in patients with chronic
liver disease.
The liver is the most commonly affected organ in patients with active brucellosis. Accordingly,
clinical and biochemical records of liver involvement have been observed in up to 50% of patients
with active disease (7). However, the molecular mechanisms involved in liver damage has been
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recently started to be elucidated. Giambartolomei and Delpino
report current understanding of the interaction between liver
structural cells including hepatocytes and hepatic stellate cells
and immune system cells during Brucella infection. They
highlight the role of the type IV secretion system (T4SS) and
the effector protein BPE005 in the activation of hepatic stellate
cells to induce fibrosis. It is likely that BPE005 could participate
in granuloma formation that might act as a reservoir of bacteria
contributing to the disease chronicity. Prior to the development
of liver fibrosis may occur events of inflammation and cell
death. The contribution of the inflammasomes activation due
to B. abortus infection on liver fibrosis was explored in an
original article. Arriola Benitez et al. demonstrate in a series
of experiments performed using the hepatic stellate cell line
LX-2, that inflammasomes NLRP3 and AIM2 are involved in
the induction of a fibrotic phenotype in hepatic stellate cells
during B. abortus infection in a mechanism that involved IL-1β.
These experiments were further corroborated using knock out
(KO) mice, and strongly suggest the main contribution of this
inflammasomes in the liver fibrosis during B. abortus infection.
In the liver fibrosis induced by Schistosoma mansoni
infection, inflammasomes has also involved. Sanches et
al. have unraveled using the murine model, the crucial
role of the NLRP6 inflammasome in the schistosomiasis-
associated hepatic granulomas. Hence, the absence of NLRP6
correlates with a significant reduction in inflammation and
collagen deposition, as well as α-SMA and IL-13 levels
as fibrotic markers. Both articles stand out the role of
inflammasomes as central contributors to liver fibrosis
triggered by infectious hepatic diseases. Moreover, parasite
worms such as Schistosoma mansoni and S. japonicum
induce a dramatic granulomatous response in liver and
intestines. Subsequently, infection may further develop
into significant fibrosis and portal hypertension. Zheng
et al. extensively review previous reports to elucidate the
contribution of T lymphocytes and their secreted cytokines in
the immunopathology of schistosomiasis. They clearly indicate
the different roles developed by the T-cell subsets for regulating
the pathological progression of schistosomiasis in the local
microenvironment. Moreover, they highlight recent findings
about Tfh and Th9 cells as promoters of liver granulomas
and fibrogenesis.
The tumor progression locus 2 (TPL2) is a serine/threonine
kinase acting as a key mediator in liver and systemic metabolic
disorders with an inflammatory component (8). However, the
function of TPL2 in regulating hepatocyte function and liver
inflammation during fulminant hepatitis is poorly understood,
Xu et al. shed light on the TPL2 role associated with the myeloid
derived suppressor cells (MDSC)-mediated protection against
fulminant hepatitis. Using the murine model, they demonstrate
that TPL2 deficiency suppresses IL-25-induced chemokine
CXCL1/2 expression in hepatocytes, thus impairing MDSC
recruitment into the liver, and increasing the infiltrate CD4+
lymphocyte proliferation that enhances fulminant hepatitis
development. These findings strongly suggest that TPL2 is a
potential target for the fulminant hepatitis treatment since it plays
a critical role in MDSC recruitment.
The interaction between HIV and liver cell population
has been previously explored. However, the relevance is still
unclear in well-controlled patients on ART. In this context,
the perspective article, Zhang and Bansal propose that during
HIV infection, changes in the biology of Kupffer cells would
create a microenvironment that drives hepatic pathology during
microbial translocation. Targeting this pathway could help to
improve liver-related consequences in HIV patients.
Liver damage associated to sterile inflammation was
evaluated in a model of Non-alcoholic fatty liver disease
(NAFLD). This pathology is associated to an excessive storage
of fatty acids in the form of triglycerides in hepatocytes
and it is considered the main causes of cirrhosis and major
risk factors for hepatocellular carcinoma and liver-related
death. Wang et al. reveal in a mice model that perforin
regulates the abundance of hepatic IFN-γ-producing
CD4+ T cells with concomitant decrease of macrophage
accumulation in liver. This indicate that perforin can act
as an immune regulator to prevent NAFLD, suggesting its
potential use to prevent hepatic steatosis and other related liver
metabolic disorders.
Finally, the last two review article focus on the potentials
therapy against liver pathology.
Excessive systemic inflammation is considered as the trigger
of liver failure. Glucocorticoids (GCs) can rapidly suppress
excessive inflammatory reactions and immune response. In a
review article, Xue and Meng describe the current knowledge
regarding glucocorticoid therapy in liver failure including
emerging information. Although, the topic was addressed from
basic research and clinical trials, the current understanding
remains inconclusive for the application of GS treatment during
liver failure.
The beneficial effect of probiotics has been extended to
liver function in cirrhosis, nonalcoholic fatty liver disease, and
alcoholic liver disease. Parker et al. review the current knowledge
of bacteria of the genusAlistipes on its protective role during liver
fibrosis among other diseases in animal models.
In summary, this Research Topic highlights the
immunopathology of liver damage due to different pathologies.
Knowledge acquired from articles contained in this special issue
are relevant to the discovery of new targets for controlling liver
inflammation and fibrosis.
We wish to express our appreciation to all the authors and
reviewers who have participated in this Research Topic.
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